Herceptin license extended
Trastuzumab (Herceptin) used in combination with an aromatase inhibitor has been approved for use in the treatment of an aggressive form of breast cancer.
Sign in
In order to continue you need to be a registered user. If you would like to register to Nursing Times then click here.
